Literature DB >> 22404843

Existing medications among non-pregnancy-related listeriosis patients in England, 2007-2009.

P Mook1, J M Jenkins, S J O'Brien, I A Gillespie.   

Abstract

To identify which medications were most commonly taken by non-pregnancy-related listeriosis patients prior to illness, we compared the medications reported by 512 cases identified via national surveillance in England between 2007 and 2009 with national prescription data, using British National Formulary (BNF) coding. Relative risks and corresponding confidence intervals were calculated, as appropriate, for BNF chapters and sections. Among listeriosis cases, the rates for cytotoxic drugs, drugs affecting the immune response and corticosteroids were significantly higher than for other medications. However, interactions between medications and how medications might confound or be confounded by concurrent medical conditions need to be investigated further. Nevertheless our findings suggest that targeting food-safety advice to prevent this foodborne disease in certain treatment groups is warranted.

Entities:  

Mesh:

Year:  2012        PMID: 22404843      PMCID: PMC9152075          DOI: 10.1017/S095026881200026X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  22 in total

1.  Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases.

Authors:  T Glück; H-J Linde; J Schölmerich; U Müller-Ladner; C Fiehn; P Bohland
Journal:  Arthritis Rheum       Date:  2002-08

2.  A national case-control study of risk factors for listeriosis in Australia.

Authors:  C B Dalton; T D Merritt; L E Unicomb; M D Kirk; R J Stafford; K Lalor
Journal:  Epidemiol Infect       Date:  2010-04-30       Impact factor: 2.451

3.  Risk factors for mortality in non-pregnancy-related listeriosis.

Authors:  P Mook; B Patel; I A Gillespie
Journal:  Epidemiol Infect       Date:  2011-06-21       Impact factor: 2.451

4.  Significant increase of listeriosis in Germany--epidemiological patterns 2001-2005.

Authors:  J Koch; K Stark
Journal:  Euro Surveill       Date:  2006

5.  Listeria infections associated with infliximab: case reports.

Authors:  Thomas Kesteman; Jean-Cyr Yombi; Jacques Gigi; Patrick Durez
Journal:  Clin Rheumatol       Date:  2007-06-20       Impact factor: 2.980

6.  Risk factors for listeriosis in Denmark, 1989-1990.

Authors:  A Jensen; W Frederiksen; P Gerner-Smidt
Journal:  Scand J Infect Dis       Date:  1994

Review 7.  Listeria monocytogenes, a food-borne pathogen.

Authors:  J M Farber; P I Peterkin
Journal:  Microbiol Rev       Date:  1991-09

8.  Disease presentation in relation to infection foci for non-pregnancy-associated human listeriosis in England and Wales, 2001 to 2007.

Authors:  Iain A Gillespie; Jim McLauchlin; Christine L Little; Celia Penman; Piers Mook; Kathie Grant; Sarah J O'Brien
Journal:  J Clin Microbiol       Date:  2009-08-12       Impact factor: 5.948

9.  Changing pattern of human listeriosis, England and Wales, 2001-2004.

Authors:  Iain A Gillespie; Jim McLauchlin; Kathie A Grant; Christine L Little; Vina Mithani; Celia Penman; Christopher Lane; Martyn Regan
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

10.  Increasing incidence of listeriosis in France and other European countries.

Authors:  Véronique Goulet; Craig Hedberg; Alban Le Monnier; Henriette de Valk
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

View more
  2 in total

1.  Risk Factors for Sporadic Non-Pregnancy Associated Listeriosis in Germany-Immunocompromised Patients and Frequently Consumed Ready-To-Eat Products.

Authors:  Karina Preußel; Astrid Milde-Busch; Patrick Schmich; Matthias Wetzstein; Klaus Stark; Dirk Werber
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

Review 2.  The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid.

Authors:  Tom C Martinsen; Reidar Fossmark; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-11-29       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.